WO1999056821A1 - Implantable seizure warning system - Google Patents

Implantable seizure warning system Download PDF

Info

Publication number
WO1999056821A1
WO1999056821A1 PCT/US1999/007937 US9907937W WO9956821A1 WO 1999056821 A1 WO1999056821 A1 WO 1999056821A1 US 9907937 W US9907937 W US 9907937W WO 9956821 A1 WO9956821 A1 WO 9956821A1
Authority
WO
WIPO (PCT)
Prior art keywords
electrode
signal
sensor
sensing
seizure
Prior art date
Application number
PCT/US1999/007937
Other languages
French (fr)
Inventor
Mark T. Rise
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to AU35542/99A priority Critical patent/AU744851B2/en
Priority to EP99917411A priority patent/EP1075306A1/en
Priority to CA002329782A priority patent/CA2329782A1/en
Publication of WO1999056821A1 publication Critical patent/WO1999056821A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128Control systems
    • A61N1/36135Control systems using physiological parameters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/40Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4094Diagnosing or monitoring seizure diseases, e.g. epilepsy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36064Epilepsy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/03Detecting, measuring or recording fluid pressure within the body other than blood pressure, e.g. cerebral pressure; Measuring pressure in body tissues or organs
    • A61B5/031Intracranial pressure

Definitions

  • This invention relates to the treatment of seizure disorders and, and more particularly relates to techniques for warning patients of an epileptic seizure. Description of Related Art
  • Epilepsy is a condition characterized by recurrent seizures which are the outward manifestation of excessive and/or hyper-synchronous abnormal electrical activity of neurons in the cerebral cortex of the brain. A seizure often occurs when the electrical activity of the brain becomes more "synchronized” as would be the case when the person is in a drowsy state.
  • a seizure patient may suffer from any combination of different types of seizures.
  • Grand mal seizures are the most common form of epilepsy and are characterized by convulsions with tonic-clonic contractions of the muscles. Absence seizures (previously referred to as "petit mal") are characterized by a brief and sudden loss of consciousness. The psychomotor form of seizures is characterized by a clouding of consciousness for one or two minutes.
  • a complex partial seizure is characterized by a complete loss of consciousness. The type of seizure experienced is typically dependent upon the function of the portion of the cerebral cortex where hypersynchronous activity is occurring. Many types of seizures generally involve the entire brain, while certain types, such as partial seizures, begin in one part of the brain and may remain local.
  • seizures significantly limit the autonomy of the patient.
  • the patient When hit with a seizure attack, the patient typically loses some level of control of his/her body. In most cases, seizures occur without prior warning to the patient.
  • epileptic seizures pose a serious safety hazard to the patient as others surrounding the patient. For example, a patient hit with a sudden seizure attack while he/she is driving a car may endanger his/her own safety as well as the safety of others. Seizure patients are also exposed to a risk of bodily harm when operating machinery and even in daily activities such as crossing a street or going down stairs.
  • researchers have developed a number of techniques for treating seizure disorders and its symptoms.
  • DBS Deep Brain Stimulation
  • infusion of certain drugs into a region of the brain can affect the excitability of the neurons at the site of infusion as disclosed in U.S. Patent No. 5,713,923 (Rise et al.) assigned to Medtronic, Inc.
  • Others have studied the effects of electrically stimulating the vagus nerve as a means of "desynchronizing" the electrical activity of the brain.
  • the developers employ two processes.
  • the first process is to extract certain features from the signals representing the electrical activity of the brain. Examples of the signal features include the signal power or the frequency spectrum of the signals.
  • the second process is to recognize a pattern or set of values for those features which characterize a brain state that will reliably lead to a seizure.
  • researchers have developed warning systems to alert the seizure patient of a possible seizure onset.
  • U.S. Patent Nos. 3,863,625 and 4,566,464 disclose epileptic seizure warning systems producing audio and visual warning signals to the patient prior to the possible onset of a seizure.
  • the warning devices are external devices which can be worn in a shirt pocket of a seizure patient. Such an approach is generally simpler in design than the above- described techniques for treatment of seizures and provides the patient prior warning of a possible seizure onset.
  • these device allows the patient to take appropriate action to minimize physical injury to the patient and others. This approach, however, requires the patient to constantly carry around the monitoring device causing inconvenience to the patient especially if the monitoring device is misplaced.
  • the use of audio and visual signals as the warning mechanism may also not be as effective if the device is buried underneath a heavy coat or is outside of the hearing range of the patient. In addition, this device is ineffective for seizure patients who have impaired vision or hearing.
  • the present invention is directed to overcoming the disadvantages of the foregoing systems.
  • a preferred form of the invention consists of a sensing portion capable of detecting the onset of a seizure, a signal processing portion, and a therapy delivery portion.
  • the sensing portion may be an electrical sensor, chemical sensor, and/or a sensor for sensing physiological changes.
  • the particular structure and parameter to measure may be selected from any known techniques which provide indication of the possible onset of a seizure.
  • the signal processing portion processes and analyzes the sensed signal using an algorithm for recognizing a pattern scheme indicative of the onset of a seizure. If a pattern indicative of the onset of a seizure is recognized, the therapy delivery portion is triggered.
  • the therapy delivery portion is preferably a stimulation electrode which delivers sensory stimulation to the patient thereby alerting the patient of the onset of a seizure.
  • Sensory stimulation may encompass any combination of touch, sight or sound stimuli.
  • the patient may then take appropriate action to avoid physical injury. For example, if the patient is driving a car when he/she is given a warning signal under the present invention, the patient may immediately stop the car. Further, research has found that the human body is capable of aborting seizures through sensory self stimulation.
  • the invention includes a sensing portion, a signal generating portion and a therapy delivery portion.
  • the sensing portion monitors electrical, chemical and or physiological activity of the patient.
  • the signal generating portion transduces the sensed activity of the patient to a corresponding electrical signal.
  • the therapy delivery portion provides sensory stimulation to the patient based on the electrical signal provided by the signal generating portion.
  • Sensory stimulation may be provided by stimulation of the dorsal column of the spinal cord. Alternatively it may be provided by stimulation of a region of the thalamus or cortex representing a sensory function such as skin sensation or sound, visual or olfactory perception.
  • the patient is thereby provided continuous sensory stimulus relating to electrical, chemical and/or physiological activity of the patient sensed by the sensing portion.
  • the patient Before the patient experiences a seizure, the patient will have sensed a certain pattern of sensory stimulus. After one or more of such seizure episodes, the patient may thereby learn to recognize patterns which are indicative of a seizure onset. By recognizing these patterns, the patient may thereby take appropriate action as discussed herein.
  • seizure disorders including epilepsy
  • seizures can be alleviated or prevented using sensory stimulation to consciously alert the patient of the onset of a seizure.
  • the patient may take action to minimize the risk of injury result from a loss of bodily control.
  • mental awareness by the patient of the possibility of a seizure in itself may thereby prevent the seizure from occurring.
  • Figure 1 is a diagrammatic illustration of a preferred embodiment of the present invention having a sensor implanted in a brain, a signal generator and stimulation electrodes;
  • Figure 2 is a diagrammatic illustration of the embodiment of Figure 1 depicting the placement of the stimulation electrodes to stimulate a predetermined site of the spinal cord;
  • Figure 3 is a block diagram of the signal processing portion of the present invention.
  • Figure 4 is a flow chart depicting the steps for alerting the patient of a possible seizure.
  • the present invention discloses techniques for providing sensory stimulation as a means for desynchronizing the electrical activity of the brain which leads to a seizure.
  • the invention includes generally a sensor portion for monitoring the onset of a seizure, a signal processing portion for processing the sensed signals to recognize a pattern indicative of a seizure onset, and a therapy delivery portion for providing sensory stimulation to alert the patient of the possible onset of a seizure.
  • a system made in accordance with the preferred embodiment may be implanted below the skin of a patient.
  • the system includes generally a sensor 20, a signal processor/generator 30 and one or more stimulation electrodes 40.
  • Sensor 20 serves as the sensing portion of the present invention.
  • Sensor 20 is implanted into a portion of a patient's body suitable for detecting a condition resulting from the onset of a seizure, including a seizure itself.
  • Sensor 20 is adapted to sense an attribute of the body that changes in advance of or during a seizure.
  • Sensor 20 is operatively coupled to provided sensed signals to the signal processor/generator 30. As shown, sensor is coupled via lead 25 to signal processor/generator 30. Alternatively, telemetry may be used to couple components 20 and 30. Signals that are received by the sensor may by amplified before transmission to signal processor/generator 30.
  • Sensor 20 may take the form of a device capable of detecting nerve cell or axon activity that is related to the pathways at the cause of a seizure symptom, or that indicates sensations which are elicited by the onset of a seizure.
  • sensor 20 is located deep in the brain parachyma in appropriate locations as shown in Figure 1 and consists of a tube 50 implanted into brain B that carries one or more depth wire electrodes near end 52 of tube 50.
  • the electrodes may be inserted into the thalamus, internal capsule, hippocampus, cortex or basal ganglia of brain B.
  • the electrodes may be inserted into the seizure focus or part of the central nervous system where seizures begin.
  • sensor 20 may include electrical transducers including subcutaneous electrodes placed on the surface of the skull over appropriate brain structures, peg electrodes implanted into the skull over these brain structures, epidural electrodes, or subdural electrodes placed on the cortical surface of appropriate brain structures.
  • brain EEG/ECoG recorded above the cortical surface also may be detected by such a sensor.
  • Sensors placed above the cortical surface may be generally located at two or more locations identified in the International 10-20 system of standard sites for EEG (Spehlmann 's EEG Primer, Second Edition, Bruce J. Fisch, Elsevier Sciences Publisher BV, 1991).
  • sensor 20 may be a chemical sensor implanted in the brain B or ventricular space for detecting certain chemical substances such as transmitter substances or the break down products of transmitter substances.
  • sensor 20 may take the form of a transducer consisting of an electrode with an ion selective coating applied which is capable of directly transducing the amount of a particular transmitter substance or its breakdown by-products found in the interstitial space of a region of the brain B such as the hippocampus or thalamus.
  • the level of the interstitial transmitter substance is an indicator of the relative activity of the brain region and the onset of a seizure.
  • An example of this type of transducer is described in the paper "Multichannel semiconductor-based electrodes for in vivo electrochemical and electro-physiological studies in rat CNS" by Craig G. van Home, Spencer Bement,
  • sensor 20 may sense physiological changes which are indicative of a seizure onset.
  • sensor 20 may transduce physiological changes in the heart rate or respiration.
  • sensor 20 may be placed near nerve cells controlling muscles and include a device capable of detecting nerve compound action potentials (e.g., either sensory afferent information from muscle or skin receptors or efferent motor potentials controlling a muscle of interest).
  • nerve compound action potentials e.g., either sensory afferent information from muscle or skin receptors or efferent motor potentials controlling a muscle of interest.
  • sensor 20 may detect muscle EMG in one, two or more muscles. Monitored muscles may include the heart, respiratory muscles or reciprocal muscles at one joint.
  • sensor 20 may take the form of a lead with one or more recording electrodes inserted into the muscle of interest.
  • sensor 20 may sense heart rate or respiration rate.
  • Sensor 20 may be physically located outside of the body and communicate with the implanted portion through telemetry.
  • the output of sensor 20 is coupled by cable 25, comprising one or more conductors, to the signal processing portion of the present invention.
  • the output of an external sensor would communicate with the implanted pulse generator through a telemetry downlink.
  • Such telemetric systems may use, for example, radio frequency, ultrasound, infrared or other like communication means.
  • the signal processing portion of the present invention is preferably included within signal processor/generator 30.
  • signal processor/generator 30 may be separated into a signal processing component and a signal generating component.
  • the signal processing portion or component provides a means for signal processing and means for pattern recognition.
  • Figure 3 is a block diagram depicting the signal processing portion of the present invention.
  • a signal received from sensor 20 may be processed by amplifying and filtering the signal by amplifier 100 and filter 200 respectively.
  • the signal is then converted to a digital representation by analog to digital converter 300.
  • the signal may then be further processed by a digital signal processing chip 400 or may be input to a microprocessor 500.
  • Microprocessor processes the sensor data in different ways depending on the type of parameter that is sensed by sensor 20.
  • Microprocessor 500 processes the sensor signal and determines whether there exists a threat of a seizure.
  • microprocessor 500 serves as the means for feature extraction and for pattern recognition.
  • digital signal processing chip 400 could be used to extract features prior to processing by the software algorithm of microprocessor 500.
  • Feature extraction and pattern recognition involves implementing an algorithm to detect the onset of a seizure.
  • the software algorithm is performed as follows. Sixteen channels of EEG waves are recorded. These EEG waves are then low-pass filtered at 70 cycles/sec with a 4-pole analog filter and then sampled at 200 samples/sec/channel. The resulting signal is then broken down into simple features by reducing the sinusoidal EEG signal into a sequences of segments. A segment is a section between two consecutive extremes of amplitude and is characterized by duration, amplitude and direction (i.e., slope of the line). A sequence of segments is created to eliminate small amplitude "noise" (beta frequency EEG, muscle artifact). This noise creates smaller intervening segments that face an opposite direction to that of the neighboring larger segments.
  • noise beta frequency EEG, muscle artifact
  • the sequence combines one or more segments which are faced in the same direction and smaller intervening segments.
  • a sequence ends when a segment not belonging to that sequence is produced.
  • a segment does not belong to a sequence when its direction is opposite to the previous segment and its length is greater than the length of the previous segment.
  • SSW EEG spike or sharp wave
  • the relative amplitude is the ratio of the amplitude of the instant sequence to the average amplitude of the previous sequences taken 5 seconds prior. If the relative amplitude is above 4, then the sequence is marked as being part of a SSW. Next, the pseudo-duration of the segment is checked. The pseudo-duration is graphically determined by extending a line from the start of a sequence (point A) through the half-way point of the actual
  • the horizontal distance from A to B is the pseudo-duration.
  • the sequence is marked as a possible SSW if the pseudo-duration in combination with the relative amplitude reaches above a certain amount. Generally, the shorter the pseudo- duration, the lower the relative amplitude needs to be for a SSW marking.
  • the relative amplitudes are checked in relation to the relative sharpness of the waves.
  • the relative sharpness of the wave is the second derivative of a wave at 15 msec before and after the apex of a wave. The higher the relative sharpness, the lower the relative amplitude required to mark the sequence as a possible SSW.
  • the total duration of the wave is checked. If it is larger or equal to 35 msec, the sequence is marked as a possible SSW.
  • a sequence or a wave is marked as a possible SSW, further processing is required to possibly reject this wave.
  • the wave is rejected if it is the result of muscle activity, eye blinks or alpha activity.
  • Muscle activity may cause a large number of high amplitude segments in the immediate surrounding of the wave (1/3 sec).
  • Eye blinks may cause SSW marking from an EEG in the frontal channel having positive polarity, has a duration larger than 150 msec, and a wave of similar amplitude occurs simultaneously on the homologous confralateral channel.
  • Alpha activity causes a dominant frequency of 8- 12 cycles/sec.
  • a wave is determined to be a SSW, its relationships with other channels are important for localization of an epileptic focus.
  • the above analysis proceeds by discrete time units of about 1/3 sec. If several SSWs are found in a given channel during a time unit, only the sharpest is retained. If SSWs are found in one or more channels within the time unit, an event is said to have occurred. The events from the 16 EEG channels may then be tabulated. Based on the location and occurrence frequency of these events, electrical activity indicating a seizure pattern may be determined.
  • Such a system may be that disclosed by J. Gotman and P.
  • the rhythmicity of the electrical activity could also be used to indicate the occurrence of a seizure.
  • the time interval associated with two successive segments is proportional to the frequency of EEG activity. Frequency of EEG activity between 3 to 20 cycles/sec sustained for a sufficient duration indicated the occurrence of a seizure. For example, once a patient suffers a seizure attack, a template may be created which can be used to detect future seizures exhibiting similar EEG activity. Such a template would be patient specific.
  • Microprocessor 500 is coupled to signal processor/generator 0 and cues the signal processor/generator 30 to generate a signal when a pattern indicative of a seizure is identified.
  • Signal processor/generator 30 is implanted in a human body in a subclavicular, subcutaneous pocket. Alternatively, the signal processor/generator 30 may be implanted elsewhere, such as in the abdomen.
  • Signal processor/generator 30 may take the form of a modified signal generator Model 7424 manufactured by Medtronic, Inc. under the trademark Itrel II which is incorporated by reference.
  • Signal processor/generator 30 may include a frequency generator, a digital to analog converter, and a pulse width control module to vary the type of stimulation to provide as a warning.
  • the stimulus pulse frequency is controlled by programming a value to the programmable frequency generator (not shown).
  • the programmable frequency generator provides an interrupt signal to signal processor/generator 30 when each stimulus pulse is to be generated.
  • the frequency generator may be implemented by model CDP1878 sold by Harris Corporation.
  • the clinician programs certain key parameters into the memory of the implanted device or may do so via telemetry. These parameters may be updated subsequently as needed. Alternatively, the clinician may elect to use default values. The clinician must program the range of values for pulse width, amplitude and frequency which microprocessor 500 may use to optimize the therapy. Stimulus parameters can be adjusted (via telemetry) by a computer algorithm within a range specified by the clinician in an attempt to optimize the seizure suppression.
  • Figure 4 discloses a flow chart for providing a patient with a seizure in accordance with the present invention.
  • sensor 20 senses a parameter of the body and generates a signal.
  • the signal is processed and, at 415, an algorithm determines whether the sensed signal indicates that there exists a risk of a seizure onset. This step is continually performed. If it is determined that a seizure onset is possible, at step 420, electrodes 40 provide electrical stimulation to provide some sort of sensory stimulus to alert the patient. Alternatively, the sensory stimulus may be strong enough such that it in itself may abort the onset of a seizure.
  • Simulation electrodes 40 serve as the therapy delivery portion of the present invention.
  • Each electrode 40 is individually connected to the signal processor/generator 30 through a wire conductor.
  • any number of electrodes may be used.
  • Model 3387 DBS electrodes sold by Medtronic, Inc. of Minneapolis, Minnesota may be used.
  • Stimulation electrodes 40 serve to produce a sensory experience for the patient based on the signal provided by the signal processor/generator 30.
  • the stimulation electrodes 40 are placed along the spinal cord in the epidural space. The exact placement of the electrodes 40 is dependent upon the type of sensory experience desired. Sensors may be placed to automatically elicit a visual, aural or touch stimulus. An alternative sound stimulus may be an speaker mechanism as found in synchromed pumps.
  • Electrodes 40 may be placed along the anterolateral aspect of the spinal cord to activate the pain fibers of the spinothalamic tract thereby creating a more painful experience.
  • Alternative placement of electrodes 40 may include the dorsal column of the spinal cord, the antero lateral column of the spinal cord, skin nerves, the auditory cortex, the somatosensory cortex, nuclei of sensory thalamus, or the visual cortex.
  • the electrodes 40 may be placed directly under the skin to produce skin senses.
  • the system includes generally a sensing portion, a signal generating portion and a therapy delivery portion.
  • the sensing portion monitors electrical, chemical and/or physiological activity of the patient.
  • the signal generating portion transduces the sensed activity of the patient to a corresponding electrical signal used to activate a pattern of sensation in one part of the sensory nervous system.
  • the signal generating portion includes generally a signal generator. Under this embodiment, means for pattern recognition, such as algorithms, would not be required.
  • the sensed signal is processed and the therapy delivery portion provides continuous sensory stimulation to the patient representative of the sensed electrical, chemical and/or physiological activity. Alternatively, the patient may receive sensory stimulus in intervals of short time periods.
  • the sensory stimulation provided includes features which are in some way related to the features extracted from the EEG/ECoG containing the most power.
  • the stimulus intensity which is determined by the pulse width and amplitude of the stimulus pulses might be related to the amplitude of the EEG/ECoG.
  • stimulus amplitude might be related to a measure of complexity as described by K. Lehnertz and C.E. Elger (“Neuronal complexity loss in temporal lobe epilepsy: effects of carbamazepine on the dynamics of the epileptogenic focus.”, Electroencephalography and clinical Neurophysiology, 103 (1997) 376-380.
  • seizure patients Over time and after one or more seizure episodes, the patient will learn to recognize the stimulation patterns which are indicative of a seizure onset.
  • the human brain which has an inherent ability to recognize patterns may thereby learn to recognize the patterns for the occurrence of seizures.
  • seizure patients may be provided adequate warning of a possible seizure onset to avoid the risk of physical injury.
  • the patient may also take action to avoid the possible onset of the seizure.

Abstract

The present invention discloses techniques for warning a patient of a possible onset of a seizure using a sensor, a signal generator and at least one implantable electrode. The electrodes are positioned to stimulate the spinal cord or under the skin. The sensor senses a parameter of the body indicative of the possible onset of a seizure. The sensor generates a sensing signal which is processed and an algorithm is utilized to determine whether the sensing signal shows a pattern indicative of a possible seizure onset. If such a pattern is recognized, the signal generator provides electrical stimulation via electrodes to generate a sensory stimulus to the body. The stimulation may provide visual, aural or touch stimulus to the patient. The patient is thereby alerted to the possibility of a seizure onset and may take appropriate action.

Description

IMPLANTABLE SEIZURE WARNING SYSTEM
Field of the Invention
This invention relates to the treatment of seizure disorders and, and more particularly relates to techniques for warning patients of an epileptic seizure. Description of Related Art
Epilepsy is a condition characterized by recurrent seizures which are the outward manifestation of excessive and/or hyper-synchronous abnormal electrical activity of neurons in the cerebral cortex of the brain. A seizure often occurs when the electrical activity of the brain becomes more "synchronized" as would be the case when the person is in a drowsy state.
A seizure patient may suffer from any combination of different types of seizures. Grand mal seizures are the most common form of epilepsy and are characterized by convulsions with tonic-clonic contractions of the muscles. Absence seizures (previously referred to as "petit mal") are characterized by a brief and sudden loss of consciousness. The psychomotor form of seizures is characterized by a clouding of consciousness for one or two minutes. A complex partial seizure is characterized by a complete loss of consciousness. The type of seizure experienced is typically dependent upon the function of the portion of the cerebral cortex where hypersynchronous activity is occurring. Many types of seizures generally involve the entire brain, while certain types, such as partial seizures, begin in one part of the brain and may remain local.
Regardless of the type of epilepsy, seizures significantly limit the autonomy of the patient. When hit with a seizure attack, the patient typically loses some level of control of his/her body. In most cases, seizures occur without prior warning to the patient. As a result, epileptic seizures pose a serious safety hazard to the patient as others surrounding the patient. For example, a patient hit with a sudden seizure attack while he/she is driving a car may endanger his/her own safety as well as the safety of others. Seizure patients are also exposed to a risk of bodily harm when operating machinery and even in daily activities such as crossing a street or going down stairs. Researchers have developed a number of techniques for treating seizure disorders and its symptoms. For example, research has shown that inhibiting (namely, reducing the excitation of neurons) the substantia nigra in the brain increases the threshold for seizure occurrence. Researchers have also found that increasing the activity of neurons in the external Globus Pallidum (GPe) increases inhibition of neurons in the subthalamic nucleus which in turn inhibits neural activity in the substantia nigra. Neurosurgeons have also been able to diminish the symptoms of many neural disorders by lesioning certain brain areas, examples being lesioning the ventral lateral portion of the internal Globus Pallidus and the Vim Thalamus for treating movement disorders. Alternatively, it has been demonstrated that open-loop Deep Brain Stimulation (DBS) at high frequencies (100 Hz or higher) of certain brain structures can alleviate, diminish, or completely stop symptoms of tremor, rigidity, akinesia or hemiballism much like creating a lesion. Electrical stimulation of the nervous system has also been used to suppress seizures. Finally, infusion of certain drugs into a region of the brain can affect the excitability of the neurons at the site of infusion as disclosed in U.S. Patent No. 5,713,923 (Rise et al.) assigned to Medtronic, Inc. Others have studied the effects of electrically stimulating the vagus nerve as a means of "desynchronizing" the electrical activity of the brain. It has been observed that stimulation of the vagus nerve with certain parameters caused de-synchronization of the brain's electrical activity in animal models. These concepts were disclosed by Zabara in U.S. Patent Nos. 4,867,164 and 5,025,807. De-synchronization can be thought of as "alerting" phenomena since it reflects active mental activity.
Under another approach, researchers have devised algorithms to detect the onset of a seizure. Qu and Gotman reported a system that recognizes patterns of electrical activity similar to a template developed from recording an actual seizure. See H. Qu and J. Gotman, "A Seizure Warning System for Long-term Epilepsy Monitoring", Neurology, 1995;45:2250-2254. Similarly, Osario et. al. have reported an algorithm applied to signals recorded from intracranial electrodes capable of 100% seizure detection rate with 0% false negatives and minimal false positives. See I. Osario, M. Frei, D. Lerner, S. Wilkinson, "A Method for Accurate Automated Real-time Seizure Detection", Epilepsia, Vol. 36, Suppl. 4, 1995. In each of these techniques for recognizing the onset of a seizure, the developers employ two processes. The first process is to extract certain features from the signals representing the electrical activity of the brain. Examples of the signal features include the signal power or the frequency spectrum of the signals. The second process is to recognize a pattern or set of values for those features which characterize a brain state that will reliably lead to a seizure. Using these pattern recognition techniques, researchers have developed warning systems to alert the seizure patient of a possible seizure onset. For example, U.S. Patent Nos. 3,863,625 and 4,566,464 disclose epileptic seizure warning systems producing audio and visual warning signals to the patient prior to the possible onset of a seizure. The warning devices are external devices which can be worn in a shirt pocket of a seizure patient. Such an approach is generally simpler in design than the above- described techniques for treatment of seizures and provides the patient prior warning of a possible seizure onset. Advantageously over the above-mentioned methods, these device allows the patient to take appropriate action to minimize physical injury to the patient and others. This approach, however, requires the patient to constantly carry around the monitoring device causing inconvenience to the patient especially if the monitoring device is misplaced. The use of audio and visual signals as the warning mechanism may also not be as effective if the device is buried underneath a heavy coat or is outside of the hearing range of the patient. In addition, this device is ineffective for seizure patients who have impaired vision or hearing. The present invention is directed to overcoming the disadvantages of the foregoing systems.
SUMMARY OF THE INVENTION As explained in more detail below, the present invention overcomes the above- noted and other shortcomings of prior techniques for warning of epileptic seizures. A preferred form of the invention consists of a sensing portion capable of detecting the onset of a seizure, a signal processing portion, and a therapy delivery portion. The sensing portion may be an electrical sensor, chemical sensor, and/or a sensor for sensing physiological changes. The particular structure and parameter to measure may be selected from any known techniques which provide indication of the possible onset of a seizure. The signal processing portion processes and analyzes the sensed signal using an algorithm for recognizing a pattern scheme indicative of the onset of a seizure. If a pattern indicative of the onset of a seizure is recognized, the therapy delivery portion is triggered. The therapy delivery portion is preferably a stimulation electrode which delivers sensory stimulation to the patient thereby alerting the patient of the onset of a seizure.
Sensory stimulation may encompass any combination of touch, sight or sound stimuli. The patient may then take appropriate action to avoid physical injury. For example, if the patient is driving a car when he/she is given a warning signal under the present invention, the patient may immediately stop the car. Further, research has found that the human body is capable of aborting seizures through sensory self stimulation.
For example, some patients who have a sensory experience associated with a partial seizure, called an aura, will slap themselves to prevent the generalized seizure that normally follows. Accordingly, under the present invention, if a patient is provided sensory stimulation warning the patient of the possibility of a seizure onset, the patient may take similar action to prevent the seizure. In fact, if the sensory stimulation is sufficiently intense, it may obviate the need for the patient to do anything since the sensory stimulation is equivalent to slapping themselves. Moreover, the cognitive recognition of the possibility of a seizure may in itself serve to abort the occurrence of the seizure. For example, the patient may engage in a mental activity such as performing mathematical computations to "de-synchronize" the neurons, thereby reducing the hypersynchronous of the neurons.
Under another embodiment, the invention includes a sensing portion, a signal generating portion and a therapy delivery portion. Under this embodiment, the sensing portion monitors electrical, chemical and or physiological activity of the patient. The signal generating portion transduces the sensed activity of the patient to a corresponding electrical signal. The therapy delivery portion provides sensory stimulation to the patient based on the electrical signal provided by the signal generating portion. Sensory stimulation may be provided by stimulation of the dorsal column of the spinal cord. Alternatively it may be provided by stimulation of a region of the thalamus or cortex representing a sensory function such as skin sensation or sound, visual or olfactory perception. The patient is thereby provided continuous sensory stimulus relating to electrical, chemical and/or physiological activity of the patient sensed by the sensing portion. Before the patient experiences a seizure, the patient will have sensed a certain pattern of sensory stimulus. After one or more of such seizure episodes, the patient may thereby learn to recognize patterns which are indicative of a seizure onset. By recognizing these patterns, the patient may thereby take appropriate action as discussed herein.
By using the foregoing techniques, seizure disorders, including epilepsy, can be treated and seizures can be alleviated or prevented using sensory stimulation to consciously alert the patient of the onset of a seizure. By alerting the patient of a possible seizure onset, the patient may take action to minimize the risk of injury result from a loss of bodily control. Moreover, mental awareness by the patient of the possibility of a seizure in itself may thereby prevent the seizure from occurring. Examples of the more important features of this invention have been broadly outlined above in order that the detailed description that follows may be better understood and so that contributions which this invention provides to the art may be better appreciated. There are, of course, additional features of the invention which will be described herein and which will be included within the subject matter of the claims appended hereto. BRIEF DESCRIPTION OF THE DRAWINGS These and other advantages and features of the invention will become apparent upon reading the following detailed description and referring to the accompanying drawings in which like numbers refer to like parts throughout and in which:
Figure 1 is a diagrammatic illustration of a preferred embodiment of the present invention having a sensor implanted in a brain, a signal generator and stimulation electrodes;
Figure 2 is a diagrammatic illustration of the embodiment of Figure 1 depicting the placement of the stimulation electrodes to stimulate a predetermined site of the spinal cord;
Figure 3 is a block diagram of the signal processing portion of the present invention; and Figure 4 is a flow chart depicting the steps for alerting the patient of a possible seizure.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention discloses techniques for providing sensory stimulation as a means for desynchronizing the electrical activity of the brain which leads to a seizure.
As preferred, the invention includes generally a sensor portion for monitoring the onset of a seizure, a signal processing portion for processing the sensed signals to recognize a pattern indicative of a seizure onset, and a therapy delivery portion for providing sensory stimulation to alert the patient of the possible onset of a seizure. Referring to Figures 1 and 2, a system made in accordance with the preferred embodiment may be implanted below the skin of a patient. The system includes generally a sensor 20, a signal processor/generator 30 and one or more stimulation electrodes 40.
Sensor 20 serves as the sensing portion of the present invention. Sensor 20 is implanted into a portion of a patient's body suitable for detecting a condition resulting from the onset of a seizure, including a seizure itself. Sensor 20 is adapted to sense an attribute of the body that changes in advance of or during a seizure. Sensor 20 is operatively coupled to provided sensed signals to the signal processor/generator 30. As shown, sensor is coupled via lead 25 to signal processor/generator 30. Alternatively, telemetry may be used to couple components 20 and 30. Signals that are received by the sensor may by amplified before transmission to signal processor/generator 30.
Sensor 20 may take the form of a device capable of detecting nerve cell or axon activity that is related to the pathways at the cause of a seizure symptom, or that indicates sensations which are elicited by the onset of a seizure. As preferred, sensor 20 is located deep in the brain parachyma in appropriate locations as shown in Figure 1 and consists of a tube 50 implanted into brain B that carries one or more depth wire electrodes near end 52 of tube 50. For such detecting, the electrodes may be inserted into the thalamus, internal capsule, hippocampus, cortex or basal ganglia of brain B. Alternatively, the electrodes may be inserted into the seizure focus or part of the central nervous system where seizures begin. In other embodiments, sensor 20 may include electrical transducers including subcutaneous electrodes placed on the surface of the skull over appropriate brain structures, peg electrodes implanted into the skull over these brain structures, epidural electrodes, or subdural electrodes placed on the cortical surface of appropriate brain structures. Under these embodiments, brain EEG/ECoG recorded above the cortical surface also may be detected by such a sensor. Sensors placed above the cortical surface may be generally located at two or more locations identified in the International 10-20 system of standard sites for EEG (Spehlmann 's EEG Primer, Second Edition, Bruce J. Fisch, Elsevier Sciences Publisher BV, 1991). Alternatively, sensor 20 may be a chemical sensor implanted in the brain B or ventricular space for detecting certain chemical substances such as transmitter substances or the break down products of transmitter substances. Under this alternative, sensor 20 may take the form of a transducer consisting of an electrode with an ion selective coating applied which is capable of directly transducing the amount of a particular transmitter substance or its breakdown by-products found in the interstitial space of a region of the brain B such as the hippocampus or thalamus. The level of the interstitial transmitter substance is an indicator of the relative activity of the brain region and the onset of a seizure. An example of this type of transducer is described in the paper "Multichannel semiconductor-based electrodes for in vivo electrochemical and electro-physiological studies in rat CNS" by Craig G. van Home, Spencer Bement,
Barry J. Hoffer, and Greg A. Gerhardt, published in Neuroscience Letters, 120 (1990) 249-252.
As yet another alternative, sensor 20 may sense physiological changes which are indicative of a seizure onset. For example, sensor 20 may transduce physiological changes in the heart rate or respiration. Under this alternative, sensor 20 may be placed near nerve cells controlling muscles and include a device capable of detecting nerve compound action potentials (e.g., either sensory afferent information from muscle or skin receptors or efferent motor potentials controlling a muscle of interest). Alternatively, sensor 20 may detect muscle EMG in one, two or more muscles. Monitored muscles may include the heart, respiratory muscles or reciprocal muscles at one joint. For such detection, sensor 20 may take the form of a lead with one or more recording electrodes inserted into the muscle of interest. In yet other embodiments, sensor 20 may sense heart rate or respiration rate. Sensor 20 may be physically located outside of the body and communicate with the implanted portion through telemetry. The output of sensor 20 is coupled by cable 25, comprising one or more conductors, to the signal processing portion of the present invention. Alternatively, the output of an external sensor would communicate with the implanted pulse generator through a telemetry downlink. Such telemetric systems may use, for example, radio frequency, ultrasound, infrared or other like communication means. The signal processing portion of the present invention is preferably included within signal processor/generator 30. Alternatively, signal processor/generator 30 may be separated into a signal processing component and a signal generating component. The signal processing portion or component provides a means for signal processing and means for pattern recognition. Figure 3 is a block diagram depicting the signal processing portion of the present invention. A signal received from sensor 20 may be processed by amplifying and filtering the signal by amplifier 100 and filter 200 respectively. The signal is then converted to a digital representation by analog to digital converter 300. The signal may then be further processed by a digital signal processing chip 400 or may be input to a microprocessor 500. Microprocessor processes the sensor data in different ways depending on the type of parameter that is sensed by sensor 20.
Microprocessor 500 processes the sensor signal and determines whether there exists a threat of a seizure. In particular, microprocessor 500 serves as the means for feature extraction and for pattern recognition. Alternatively, digital signal processing chip 400 could be used to extract features prior to processing by the software algorithm of microprocessor 500. Feature extraction and pattern recognition involves implementing an algorithm to detect the onset of a seizure.
In a preferred embodiment, the software algorithm is performed as follows. Sixteen channels of EEG waves are recorded. These EEG waves are then low-pass filtered at 70 cycles/sec with a 4-pole analog filter and then sampled at 200 samples/sec/channel. The resulting signal is then broken down into simple features by reducing the sinusoidal EEG signal into a sequences of segments. A segment is a section between two consecutive extremes of amplitude and is characterized by duration, amplitude and direction (i.e., slope of the line). A sequence of segments is created to eliminate small amplitude "noise" (beta frequency EEG, muscle artifact). This noise creates smaller intervening segments that face an opposite direction to that of the neighboring larger segments. The sequence combines one or more segments which are faced in the same direction and smaller intervening segments. A sequence ends when a segment not belonging to that sequence is produced. A segment does not belong to a sequence when its direction is opposite to the previous segment and its length is greater than the length of the previous segment. When a sequence is complete, the following operations take place sequentially to determine whether a possible EEG spike or sharp wave (SSW) is detected. First, the relative amplitude of the current sequence and of the preceding one is checked to determine whether they are above a certain threshold. The relative amplitude is the amplitude of the sequence relative to the average amplitudes of the sequences 5 seconds prior to the instant sequence. The relative amplitude is the ratio of the amplitude of the instant sequence to the average amplitude of the previous sequences taken 5 seconds prior. If the relative amplitude is above 4, then the sequence is marked as being part of a SSW. Next, the pseudo-duration of the segment is checked. The pseudo-duration is graphically determined by extending a line from the start of a sequence (point A) through the half-way point of the actual
EEG wave and extending it so its end (point B) equals the amplitude level of the ending point of the sequence. The horizontal distance from A to B is the pseudo-duration. The sequence is marked as a possible SSW if the pseudo-duration in combination with the relative amplitude reaches above a certain amount. Generally, the shorter the pseudo- duration, the lower the relative amplitude needs to be for a SSW marking. Next, the relative amplitudes are checked in relation to the relative sharpness of the waves. The relative sharpness of the wave is the second derivative of a wave at 15 msec before and after the apex of a wave. The higher the relative sharpness, the lower the relative amplitude required to mark the sequence as a possible SSW. Finally, the total duration of the wave is checked. If it is larger or equal to 35 msec, the sequence is marked as a possible SSW.
Once a sequence or a wave is marked as a possible SSW, further processing is required to possibly reject this wave. For example, the wave is rejected if it is the result of muscle activity, eye blinks or alpha activity. Muscle activity may cause a large number of high amplitude segments in the immediate surrounding of the wave (1/3 sec). Eye blinks may cause SSW marking from an EEG in the frontal channel having positive polarity, has a duration larger than 150 msec, and a wave of similar amplitude occurs simultaneously on the homologous confralateral channel. Alpha activity causes a dominant frequency of 8- 12 cycles/sec.
Once a wave is determined to be a SSW, its relationships with other channels are important for localization of an epileptic focus. The above analysis proceeds by discrete time units of about 1/3 sec. If several SSWs are found in a given channel during a time unit, only the sharpest is retained. If SSWs are found in one or more channels within the time unit, an event is said to have occurred. The events from the 16 EEG channels may then be tabulated. Based on the location and occurrence frequency of these events, electrical activity indicating a seizure pattern may be determined. Such a system may be that disclosed by J. Gotman and P. Gloor in Automatic Recognition and Quanitification oflnterictal Epileptic Activity in the Human Scalp EEG, Electroencephalography and Clinical Neurophysiology, 41 : 513-529, 1976. The rhythmicity of the electrical activity could also be used to indicate the occurrence of a seizure. The time interval associated with two successive segments is proportional to the frequency of EEG activity. Frequency of EEG activity between 3 to 20 cycles/sec sustained for a sufficient duration indicated the occurrence of a seizure. For example, once a patient suffers a seizure attack, a template may be created which can be used to detect future seizures exhibiting similar EEG activity. Such a template would be patient specific.
Other examples of algorithms to detect the onset of seizures have been reported in U.S. Patent Nos. 5,311,876 (issue May 17, 1994) and 5,349,962 (issued Sept. 27, 1994) and by Jean Gotman in Epilepsy Surgery, ch. 36 (ed. Hans, Luders, Raven Press, New York 1991) and Ivan Osorio & Mark Frei in Abstracts of the American Epilepsy Society meeting, 1995. These references are incorporated herein by reference. Those skilled in the art will appreciate that any number of other algorithms may be used. An external electronic device may be implemented to telemeter parameter changes or newer algorithms to the implanted signal processing device to adapt the detection algorithm to the particular patient.
Microprocessor 500 is coupled to signal processor/generator 0 and cues the signal processor/generator 30 to generate a signal when a pattern indicative of a seizure is identified. Signal processor/generator 30 is implanted in a human body in a subclavicular, subcutaneous pocket. Alternatively, the signal processor/generator 30 may be implanted elsewhere, such as in the abdomen. Signal processor/generator 30 may take the form of a modified signal generator Model 7424 manufactured by Medtronic, Inc. under the trademark Itrel II which is incorporated by reference. Signal processor/generator 30 may include a frequency generator, a digital to analog converter, and a pulse width control module to vary the type of stimulation to provide as a warning. The stimulus pulse frequency is controlled by programming a value to the programmable frequency generator (not shown). The programmable frequency generator provides an interrupt signal to signal processor/generator 30 when each stimulus pulse is to be generated. The frequency generator may be implemented by model CDP1878 sold by Harris Corporation. At the time the present invention is implanted within the patient, the clinician programs certain key parameters into the memory of the implanted device or may do so via telemetry. These parameters may be updated subsequently as needed. Alternatively, the clinician may elect to use default values. The clinician must program the range of values for pulse width, amplitude and frequency which microprocessor 500 may use to optimize the therapy. Stimulus parameters can be adjusted (via telemetry) by a computer algorithm within a range specified by the clinician in an attempt to optimize the seizure suppression.
Figure 4 discloses a flow chart for providing a patient with a seizure in accordance with the present invention. At step 405, sensor 20 senses a parameter of the body and generates a signal. At step 410, the signal is processed and, at 415, an algorithm determines whether the sensed signal indicates that there exists a risk of a seizure onset. This step is continually performed. If it is determined that a seizure onset is possible, at step 420, electrodes 40 provide electrical stimulation to provide some sort of sensory stimulus to alert the patient. Alternatively, the sensory stimulus may be strong enough such that it in itself may abort the onset of a seizure.
Simulation electrodes 40 serve as the therapy delivery portion of the present invention. Each electrode 40 is individually connected to the signal processor/generator 30 through a wire conductor. Depending upon the stimulus desired, any number of electrodes may be used. Model 3387 DBS electrodes sold by Medtronic, Inc. of Minneapolis, Minnesota may be used. Stimulation electrodes 40 serve to produce a sensory experience for the patient based on the signal provided by the signal processor/generator 30. Under the embodiment of Figure 1, the stimulation electrodes 40 are placed along the spinal cord in the epidural space. The exact placement of the electrodes 40 is dependent upon the type of sensory experience desired. Sensors may be placed to automatically elicit a visual, aural or touch stimulus. An alternative sound stimulus may be an speaker mechanism as found in synchromed pumps. For example, Synchromed® model 8616 pump sold by Medtronic, Inc. may be used. Alternatively, sound may be generated via a piezoelectric sound generator. Alternatively, any combination of touch stimulus, sight stimulus and sound stimulus may be utilized. In another application, a large sensory stimulus may be desired where the sensory stimulus in itself would serve to prevent the onset of a seizure. In such a case, electrodes 40 may be placed along the anterolateral aspect of the spinal cord to activate the pain fibers of the spinothalamic tract thereby creating a more painful experience. Alternative placement of electrodes 40 may include the dorsal column of the spinal cord, the antero lateral column of the spinal cord, skin nerves, the auditory cortex, the somatosensory cortex, nuclei of sensory thalamus, or the visual cortex.
Yet another arrangement is placement of the electrodes 40 over the somatosensory cortex either by using peg electrodes in the skull (to sense EEG) or epidural electrodes slipped under the skull through a burr hole to stimulate the cortex. Still another option is use of a steerable electrode to allow changes to the desired sensory stimulus. Such an electrode is disclosed U.S. Patent Application Serial No. 08/637,361 filed April 25, 1996 and entitled "Techniques for Adjusting the Locus of Excitation of Neural Tissue in the Spinal Cord or Brain." As another embodiment, electrodes 40 may be placed directly under the skin to produce skin senses. In accordance with another embodiment of the present invention, the system includes generally a sensing portion, a signal generating portion and a therapy delivery portion. Under this embodiment, the sensing portion monitors electrical, chemical and/or physiological activity of the patient. The signal generating portion transduces the sensed activity of the patient to a corresponding electrical signal used to activate a pattern of sensation in one part of the sensory nervous system. The signal generating portion includes generally a signal generator. Under this embodiment, means for pattern recognition, such as algorithms, would not be required. The sensed signal is processed and the therapy delivery portion provides continuous sensory stimulation to the patient representative of the sensed electrical, chemical and/or physiological activity. Alternatively, the patient may receive sensory stimulus in intervals of short time periods.
For example intervals of 1-10 seconds may be utilized. Rather than provide the patient with sensory stimulation only when a possible seizure onset is calculated, the patient is provided continuous stimulation. The sensory stimulation provided includes features which are in some way related to the features extracted from the EEG/ECoG containing the most power. The stimulus intensity which is determined by the pulse width and amplitude of the stimulus pulses might be related to the amplitude of the EEG/ECoG. Alternatively, stimulus amplitude might be related to a measure of complexity as described by K. Lehnertz and C.E. Elger ("Neuronal complexity loss in temporal lobe epilepsy: effects of carbamazepine on the dynamics of the epileptogenic focus.", Electroencephalography and clinical Neurophysiology, 103 (1997) 376-380. Over time and after one or more seizure episodes, the patient will learn to recognize the stimulation patterns which are indicative of a seizure onset. The human brain which has an inherent ability to recognize patterns may thereby learn to recognize the patterns for the occurrence of seizures. By using the foregoing techniques for electrical stimulation, seizure patients may be provided adequate warning of a possible seizure onset to avoid the risk of physical injury. The patient may also take action to avoid the possible onset of the seizure.
Those skilled in that art will recognize that the preferred embodiments may be altered or amended without departing from the true spirit and scope of the invention, as defined in the accompanying claims.

Claims

I CLAIM:
1. A method of warning a patient of a possible onset of a seizure using a sensor, a signal generator and at least one implantable electrode having a proximal end and a stimulation portion, the method comprising the steps of: surgically implanting the sensor within a body of a patient; coupling the sensor to the signal generator; surgically implanting the electrode in the body, coupling the proximal end to the signal generator, and positioning the stimulation portion to be in communication with neural tissue within the body; and sensing a parameter of the body with the sensor and generating a sensing signal; processing the sensing signal by the signal generator to recognize a pattern indicative of the onset of a seizure; and if the pattern is recognized, stimulating the neural tissue with the electrode to generate a sensory stimulus to the body.
2. The method of claim 1 , wherein the step of surgically implanting the sensor includes the step of positioning the sensor to be in communication with a predetermined site in a brain.
3. The method of claim 2, wherein the step of positioning includes the step of selecting the predetermined site from the group consisting of the thalamus, internal capsule, hippocampus, cortex and basal ganglia.
4. The method of claim 1 , wherein the step of sensing includes the step of sensing electrical activity of a brain.
5. The method of claim 1 , wherein the step of sensing includes the step of sensing chemical activity of a brain.
6. The method of claim 1 , wherein the step of surgically implanting includes the step of surgically implanting the signal generator.
7. The method of claim 6, wherein the step of surgically implanting the signal generator includes the step of placing the signal generator in a subclavicular, subcutaneous pocket of the body.
8. The method of claim 6, wherein the step of surgically implanting the signal generator includes the step of placing the signal generator in an abdomen of the body.
9. The method of claim 1 , wherein the step of processing the sensing signal includes the step of performing an algorithmic operation.
10. The method of claim 9, further comprising the step of changing the algorithmic operation to a second algorithmic operation.
11. The method of claim 1 , wherein the step of stimulating includes the providing a type of stimulus selected from the group consisting of touch stimulus, visual stimulus, and aural stimulus.
12. The method of claim 1 , wherein the step of surgically implanting the electrode includes the step of positioning the electrode to be in communication with a predetermined part of a spinal cord of the body.
13. The method of claim 12, wherein the step of positioning includes the step of selecting the predetermined part from the group consisting of an epidural space, dorsal aspect, anterolateral aspect, and spinothalamic tract.
14. The method of claim 1 , wherein the step of surgically implanting the electrode includes the step of positioning the electrode to be in communication with a somatosensory cortex of the brain.
15. The method of claim 1 , wherein the step of surgically implanting the electrode includes the step of positioning the electrode to be in communication neural tissue underneath skin tissue of the body.
16. An apparatus for warning a patient of a possible onset of a seizure comprising: an implantable sensor capable of generating a sensing signal; a signal processor coupled to receive the sensing signal and having means for signal processing, means for pattern recognition, and a signal generator for generating a stimulation signal; and at least one electrode having a proximal end and stimulation portion, the proximal end being coupled to receive the stimulation signal, the stimulation portion coupled to stimulate neural tissue.
17. The apparatus of claim 16, wherein the implantable sensor comprises at least one sensing electrode.
18. The apparatus of claim 17, wherein the sensing electrode is selected from the group consisting of a peg electrode, epidural electrode, subdural electrode, and a subcutaneous electrode.
19. The apparatus of claim 16, wherein the implantable sensor includes a transducer and a sensing electrode having an ion selective coating.
20. The apparatus of claim 16, wherein the implantable sensor has means for sensing physiological changes of a body.
21. The apparatus of claim 16, wherein the means for signal processor includes an analog to digital converter, an amplifier and a filter.
22. The apparatus of claim 16, wherein the means for signal processing includes a microprocessor.
23. The apparatus of claim 16, wherein the means for pattern recognition includes a microprocessor.
24. The apparatus of claim 16, wherein the signal processor is an external device further comprising means for telemetrically communicating with the sensor and the electrode.
25. The apparatus of claim 16, wherein the signal generator further comprises a frequency generator, a digital to analog converter, and a pulse width control module.
26. The apparatus of claim 16, wherein the electrode is a steerable electrode.
27. A method of warning a patient of a possible onset of a seizure using a sensor, a signal generator and at least one implantable electrode having a proximal end and a stimulation portion, the method comprising the steps of: surgically implanting the sensor within a body of a patient; sensing a parameter of the body and generating a sensing signal; coupling the signal generator to receive the sensing signal and to generate a therapy signal based on the sensing signal; surgically implanting the electrode in the body, coupling the proximal end to receive the therapy signal, and positioning the stimulation portion to be in communication with neural tissue within the body; and periodically stimulating the neural tissue to generate a sensory stimulus based on the therapy signal.
28. A method of preventing the onset of a seizure using a sensor, a signal generator and at least one implantable electrode having a proximal end and a stimulation portion, the method comprising the steps of: surgically implanting the sensor within a body of a patient; coupling the sensor to the signal generator; surgically implanting the electrode in the body, coupling the proximal end to the signal generator, and positioning the stimulation portion to be in communication with neural tissue within the body; and sensing a parameter of the body with the sensor and generating a sensing signal; processing the sensing signal by the signal generator to recognize a pattern indicative of the onset of a seizure; and if the pattern is recognized, providing a sensory stimulus to the neural tissue with the electrode to responsively initiate desynchronization of neural activity.
29. The method of claim 28, wherein the step of providing sensory stimulus includes the step of stimulating a predetermined portion of the neural tissue, the predetermined portion being selected from the group consisting of a dorsal column of a spinal cord, an antero lateral column of the spinal cord, skin nerves, auditory cortex, somatosensory cortex, nuclei of sensory thalamus, and visual cortex.
PCT/US1999/007937 1998-04-30 1999-04-12 Implantable seizure warning system WO1999056821A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU35542/99A AU744851B2 (en) 1998-04-30 1999-04-12 Implantable seizure warning system
EP99917411A EP1075306A1 (en) 1998-04-30 1999-04-12 Implantable seizure warning system
CA002329782A CA2329782A1 (en) 1998-04-30 1999-04-12 Implantable seizure warning system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/069,917 1998-04-30
US09/069,917 US6018682A (en) 1998-04-30 1998-04-30 Implantable seizure warning system

Publications (1)

Publication Number Publication Date
WO1999056821A1 true WO1999056821A1 (en) 1999-11-11

Family

ID=22092010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007937 WO1999056821A1 (en) 1998-04-30 1999-04-12 Implantable seizure warning system

Country Status (5)

Country Link
US (2) US6018682A (en)
EP (1) EP1075306A1 (en)
AU (1) AU744851B2 (en)
CA (1) CA2329782A1 (en)
WO (1) WO1999056821A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7206632B2 (en) 2003-10-02 2007-04-17 Medtronic, Inc. Patient sensory response evaluation for neuromodulation efficacy rating
WO2009055866A1 (en) * 2007-10-31 2009-05-07 Cochlear Limited Implantable medical prothesis system capable of detecting symptoms of medical conditions
US7676263B2 (en) 2006-06-23 2010-03-09 Neurovista Corporation Minimally invasive system for selecting patient-specific therapy parameters
US7747325B2 (en) 1998-08-05 2010-06-29 Neurovista Corporation Systems and methods for monitoring a patient's neurological disease state
US7853329B2 (en) 1998-08-05 2010-12-14 Neurovista Corporation Monitoring efficacy of neural modulation therapy
WO2011072684A1 (en) 2009-12-16 2011-06-23 Ictalcare A/S A system for the prediction of epileptic seizures
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US8725243B2 (en) 2005-12-28 2014-05-13 Cyberonics, Inc. Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US8762065B2 (en) 1998-08-05 2014-06-24 Cyberonics, Inc. Closed-loop feedback-driven neuromodulation
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US8868172B2 (en) 2005-12-28 2014-10-21 Cyberonics, Inc. Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
US9042988B2 (en) 1998-08-05 2015-05-26 Cyberonics, Inc. Closed-loop vagus nerve stimulation
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US9375573B2 (en) 1998-08-05 2016-06-28 Cyberonics, Inc. Systems and methods for monitoring a patient's neurological disease state
US9415222B2 (en) 1998-08-05 2016-08-16 Cyberonics, Inc. Monitoring an epilepsy disease state with a supervisory module
US9421373B2 (en) 1998-08-05 2016-08-23 Cyberonics, Inc. Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US9622675B2 (en) 2007-01-25 2017-04-18 Cyberonics, Inc. Communication error alerting in an epilepsy monitoring system
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
US9898656B2 (en) 2007-01-25 2018-02-20 Cyberonics, Inc. Systems and methods for identifying a contra-ictal condition in a subject
US11406317B2 (en) 2007-12-28 2022-08-09 Livanova Usa, Inc. Method for detecting neurological and clinical manifestations of a seizure

Families Citing this family (268)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020169485A1 (en) 1995-10-16 2002-11-14 Neuropace, Inc. Differential neurostimulation therapy driven by physiological context
US6944501B1 (en) * 2000-04-05 2005-09-13 Neurospace, Inc. Neurostimulator involving stimulation strategies and process for using it
US6459936B2 (en) * 1997-10-27 2002-10-01 Neuropace, Inc. Methods for responsively treating neurological disorders
US6354299B1 (en) * 1997-10-27 2002-03-12 Neuropace, Inc. Implantable device for patient communication
US6227203B1 (en) 1998-02-12 2001-05-08 Medtronic, Inc. Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion
US7403820B2 (en) * 1998-08-05 2008-07-22 Neurovista Corporation Closed-loop feedback-driven neuromodulation
US7277758B2 (en) * 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
US7974696B1 (en) 1998-08-05 2011-07-05 Dilorenzo Biomedical, Llc Closed-loop autonomic neuromodulation for optimal control of neurological and metabolic disease
US7231254B2 (en) * 1998-08-05 2007-06-12 Bioneuronics Corporation Closed-loop feedback-driven neuromodulation
AU5900299A (en) 1998-08-24 2000-03-14 Emory University Method and apparatus for predicting the onset of seizures based on features derived from signals indicative of brain activity
US6341236B1 (en) * 1999-04-30 2002-01-22 Ivan Osorio Vagal nerve stimulation techniques for treatment of epileptic seizures
US6876991B1 (en) 1999-11-08 2005-04-05 Collaborative Decision Platforms, Llc. System, method and computer program product for a collaborative decision platform
US6873872B2 (en) * 1999-12-07 2005-03-29 George Mason University Adaptive electric field modulation of neural systems
DE60027459T2 (en) 1999-12-07 2006-12-21 George Mason University ADAPTIVE MODULATION OF AN ELECTRIC FIELD FOR NEURAL SYSTEMS
US6473639B1 (en) 2000-03-02 2002-10-29 Neuropace, Inc. Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures
US6466822B1 (en) 2000-04-05 2002-10-15 Neuropace, Inc. Multimodal neurostimulator and process of using it
US6447500B1 (en) * 2000-04-28 2002-09-10 Medtronic, Inc. Brain fluid ion concentration modification for treating neurological disorders
US20040073099A1 (en) * 2000-04-28 2004-04-15 Medtronic, Inc. Brain fluid ion concentration modification for treating neurological disorders
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20040176831A1 (en) * 2000-07-13 2004-09-09 Gliner Bradford Evan Apparatuses and systems for applying electrical stimulation to a patient
US20030125786A1 (en) * 2000-07-13 2003-07-03 Gliner Bradford Evan Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7831305B2 (en) 2001-10-15 2010-11-09 Advanced Neuromodulation Systems, Inc. Neural stimulation system and method responsive to collateral neural activity
US20050021118A1 (en) * 2000-07-13 2005-01-27 Chris Genau Apparatuses and systems for applying electrical stimulation to a patient
US7672730B2 (en) 2001-03-08 2010-03-02 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7236831B2 (en) * 2000-07-13 2007-06-26 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7010351B2 (en) * 2000-07-13 2006-03-07 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7024247B2 (en) * 2001-10-15 2006-04-04 Northstar Neuroscience, Inc. Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures
US7305268B2 (en) 2000-07-13 2007-12-04 Northstar Neurscience, Inc. Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US7146217B2 (en) * 2000-07-13 2006-12-05 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a change in a neural-function of a patient
US7756584B2 (en) * 2000-07-13 2010-07-13 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US6871099B1 (en) * 2000-08-18 2005-03-22 Advanced Bionics Corporation Fully implantable microstimulator for spinal cord stimulation as a therapy for chronic pain
US6678548B1 (en) 2000-10-20 2004-01-13 The Trustees Of The University Of Pennsylvania Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device
US6529774B1 (en) 2000-11-09 2003-03-04 Neuropace, Inc. Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation
US6594524B2 (en) * 2000-12-12 2003-07-15 The Trustees Of The University Of Pennsylvania Adaptive method and apparatus for forecasting and controlling neurological disturbances under a multi-level control
US6597953B2 (en) * 2001-02-20 2003-07-22 Neuropace, Inc. Furcated sensing and stimulation lead
US7299096B2 (en) * 2001-03-08 2007-11-20 Northstar Neuroscience, Inc. System and method for treating Parkinson's Disease and other movement disorders
US6671555B2 (en) * 2001-04-27 2003-12-30 Medtronic, Inc. Closed loop neuromodulation for suppression of epileptic activity
US6978183B2 (en) * 2001-05-04 2005-12-20 The Washington University System and method for cooling the cortex to treat neocordical seizures
US6810285B2 (en) * 2001-06-28 2004-10-26 Neuropace, Inc. Seizure sensing and detection using an implantable device
US6606521B2 (en) 2001-07-09 2003-08-12 Neuropace, Inc. Implantable medical lead
WO2003026736A2 (en) * 2001-09-28 2003-04-03 Northstar Neuroscience, Inc. Methods and implantable apparatus for electrical therapy
US7136695B2 (en) * 2001-10-12 2006-11-14 Pless Benjamin D Patient-specific template development for neurological event detection
US7383283B2 (en) * 2001-10-16 2008-06-03 Joseph Carrabis Programable method and apparatus for real-time adaptation of presentations to individuals
US8655804B2 (en) 2002-02-07 2014-02-18 Next Stage Evolution, Llc System and method for determining a characteristic of an individual
US8195597B2 (en) * 2002-02-07 2012-06-05 Joseph Carrabis System and method for obtaining subtextual information regarding an interaction between an individual and a programmable device
US20040048795A1 (en) * 2002-02-26 2004-03-11 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US7221981B2 (en) * 2002-03-28 2007-05-22 Northstar Neuroscience, Inc. Electrode geometries for efficient neural stimulation
US6735467B2 (en) 2002-04-15 2004-05-11 Persyst Development Corporation Method and system for detecting seizures using electroencephalograms
US20040199482A1 (en) * 2002-04-15 2004-10-07 Wilson Scott B. Systems and methods for automatic and incremental learning of patient states from biomedical signals
US6937891B2 (en) * 2002-04-26 2005-08-30 Medtronic, Inc. Independent therapy programs in an implantable medical device
US7003352B1 (en) 2002-05-24 2006-02-21 Advanced Bionics Corporation Treatment of epilepsy by brain stimulation
US20040049121A1 (en) * 2002-09-06 2004-03-11 Uri Yaron Positioning system for neurological procedures in the brain
US7277748B2 (en) * 2002-09-13 2007-10-02 Neuropace, Inc. Spatiotemporal pattern recognition for neurological event detection and prediction in an implantable device
US20050075679A1 (en) * 2002-09-30 2005-04-07 Gliner Bradford E. Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system
EP1553998A2 (en) * 2002-10-07 2005-07-20 Novo Nordisk A/S Fluid delivery system with electro-muscle stimulation feature
US20050075670A1 (en) * 2002-10-07 2005-04-07 Henrik Bengtsson Signal device with electro-muscle stimulation feature
EP1565102A4 (en) 2002-10-15 2008-05-28 Medtronic Inc Synchronization and calibration of clocks for a medical device and calibrated clock
US20040153436A1 (en) * 2002-10-15 2004-08-05 Pope Cameron A. Automated information management system and methods
EP1558129B1 (en) * 2002-10-15 2009-11-25 Medtronic, Inc. Phase shifting of neurological signals in a medical device system
AU2003301370A1 (en) * 2002-10-15 2004-05-04 Medtronic Inc. Multi-modal operation of a medical device system
US20040138518A1 (en) * 2002-10-15 2004-07-15 Medtronic, Inc. Medical device system with relaying module for treatment of nervous system disorders
AU2003287162A1 (en) * 2002-10-15 2004-05-04 Medtronic Inc. Configuring and testing treatment therapy parameters for a medical device system
EP1558330A4 (en) * 2002-10-15 2008-10-01 Medtronic Inc Cycle mode providing redundant back-up to ensure termination of treatment therapy in a medical device system
US8738136B2 (en) * 2002-10-15 2014-05-27 Medtronic, Inc. Clustering of recorded patient neurological activity to determine length of a neurological event
EP1562674A4 (en) * 2002-10-15 2008-10-08 Medtronic Inc Control of treatment therapy during start-up and during operation of a medical device system
AU2003301481A1 (en) * 2002-10-15 2004-05-04 Medtronic Inc. Channel-selective blanking for a medical device system
WO2004036372A2 (en) * 2002-10-15 2004-04-29 Medtronic Inc. Scoring of sensed neurological signals for use with a medical device system
WO2004034880A2 (en) * 2002-10-15 2004-04-29 Medtronic Inc. Timed delay for redelivery of treatment therapy for a medical device system
WO2004034879A2 (en) * 2002-10-15 2004-04-29 Medtronic Inc. Screening techniques for management of a nervous system disorder
WO2004034885A2 (en) 2002-10-15 2004-04-29 Medtronic Inc. Signal quality monitoring and control for a medical device system
JP2006503323A (en) * 2002-10-17 2006-01-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Sinusoidal audio coding with phase update
US7236830B2 (en) 2002-12-10 2007-06-26 Northstar Neuroscience, Inc. Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders
US20050075680A1 (en) * 2003-04-18 2005-04-07 Lowry David Warren Methods and systems for intracranial neurostimulation and/or sensing
US7302298B2 (en) * 2002-11-27 2007-11-27 Northstar Neuroscience, Inc Methods and systems employing intracranial electrodes for neurostimulation and/or electroencephalography
US7565199B2 (en) * 2002-12-09 2009-07-21 Advanced Neuromodulation Systems, Inc. Methods for treating and/or collecting information regarding neurological disorders, including language disorders
US6959215B2 (en) * 2002-12-09 2005-10-25 Northstar Neuroscience, Inc. Methods for treating essential tremor
WO2005000153A2 (en) * 2003-04-24 2005-01-06 Northstar Neuroscience, Inc. Systems and methods for facilitating and/or effectuating development, rehabilitation, restoration, and/or recovery of visual function through neural stimulation
US7738952B2 (en) 2003-06-09 2010-06-15 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system
US7149574B2 (en) 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
AU2004261290A1 (en) * 2003-08-01 2005-02-10 Northstar Neuroscience, Inc. Apparatus and methods for applying neural stimulation to a patient
US20050143378A1 (en) 2003-12-29 2005-06-30 Yun Anthony J. Treatment of conditions through pharmacological modulation of the autonomic nervous system
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US9050469B1 (en) 2003-11-26 2015-06-09 Flint Hills Scientific, Llc Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US8060207B2 (en) * 2003-12-22 2011-11-15 Boston Scientific Scimed, Inc. Method of intravascularly delivering stimulation leads into direct contact with tissue
US20050137646A1 (en) * 2003-12-22 2005-06-23 Scimed Life Systems, Inc. Method of intravascularly delivering stimulation leads into brain
US7676269B2 (en) * 2003-12-29 2010-03-09 Palo Alto Investors Treatment of female fertility conditions through modulation of the autonomic nervous system
US7295875B2 (en) * 2004-02-20 2007-11-13 Boston Scientific Scimed, Inc. Method of stimulating/sensing brain with combination of intravascularly and non-vascularly delivered leads
US7177702B2 (en) 2004-03-12 2007-02-13 Scimed Life Systems, Inc. Collapsible/expandable electrode leads
US20050203366A1 (en) * 2004-03-12 2005-09-15 Donoghue John P. Neurological event monitoring and therapy systems and related methods
US7590454B2 (en) * 2004-03-12 2009-09-15 Boston Scientific Neuromodulation Corporation Modular stimulation lead network
US20050203600A1 (en) 2004-03-12 2005-09-15 Scimed Life Systems, Inc. Collapsible/expandable tubular electrode leads
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
JP2007530586A (en) * 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ Nervous hemostasis
US20160250097A9 (en) * 2004-03-25 2016-09-01 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
US8024036B2 (en) * 2007-03-19 2011-09-20 The Invention Science Fund I, Llc Lumen-traveling biological interface device and method of use
US7998060B2 (en) * 2004-04-19 2011-08-16 The Invention Science Fund I, Llc Lumen-traveling delivery device
US8092549B2 (en) 2004-09-24 2012-01-10 The Invention Science Fund I, Llc Ciliated stent-like-system
US8337482B2 (en) * 2004-04-19 2012-12-25 The Invention Science Fund I, Llc System for perfusion management
US20070010868A1 (en) * 2004-04-19 2007-01-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Lumenally-active device
US8353896B2 (en) * 2004-04-19 2013-01-15 The Invention Science Fund I, Llc Controllable release nasal system
US9011329B2 (en) * 2004-04-19 2015-04-21 Searete Llc Lumenally-active device
US8361013B2 (en) * 2004-04-19 2013-01-29 The Invention Science Fund I, Llc Telescoping perfusion management system
US7850676B2 (en) * 2004-04-19 2010-12-14 The Invention Science Fund I, Llc System with a reservoir for perfusion management
US20070244520A1 (en) * 2004-04-19 2007-10-18 Searete Llc Lumen-traveling biological interface device and method of use
US7857767B2 (en) * 2004-04-19 2010-12-28 Invention Science Fund I, Llc Lumen-traveling device
US8512219B2 (en) 2004-04-19 2013-08-20 The Invention Science Fund I, Llc Bioelectromagnetic interface system
US20050234440A1 (en) * 2004-04-19 2005-10-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System with a sensor for perfusion management
US8412348B2 (en) 2004-05-06 2013-04-02 Boston Scientific Neuromodulation Corporation Intravascular self-anchoring integrated tubular electrode body
US7899527B2 (en) * 2004-05-13 2011-03-01 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
US20100260669A1 (en) * 2004-05-13 2010-10-14 Anthony Joonkyoo Yun Treatment of Seasonal Conditions Through Modulation of the Autonomic Nervous System
US7483747B2 (en) * 2004-07-15 2009-01-27 Northstar Neuroscience, Inc. Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
US7286879B2 (en) 2004-07-16 2007-10-23 Boston Scientific Scimed, Inc. Method of stimulating fastigium nucleus to treat neurological disorders
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20060049957A1 (en) * 2004-08-13 2006-03-09 Surgenor Timothy R Biological interface systems with controlled device selector and related methods
US8560041B2 (en) * 2004-10-04 2013-10-15 Braingate Co., Llc Biological interface system
US7613520B2 (en) * 2004-10-21 2009-11-03 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
US7565200B2 (en) 2004-11-12 2009-07-21 Advanced Neuromodulation Systems, Inc. Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects
US20060106430A1 (en) * 2004-11-12 2006-05-18 Brad Fowler Electrode configurations for reducing invasiveness and/or enhancing neural stimulation efficacy, and associated methods
US7937160B2 (en) * 2004-12-10 2011-05-03 Boston Scientific Neuromodulation Corporation Methods for delivering cortical electrode leads into patient's head
US7366571B2 (en) * 2004-12-10 2008-04-29 Cyberonics, Inc. Neurostimulator with activation based on changes in body temperature
US7341562B2 (en) * 2004-12-15 2008-03-11 Neuropace, Inc. Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders
US7819812B2 (en) 2004-12-15 2010-10-26 Neuropace, Inc. Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders
US8214035B2 (en) * 2004-12-17 2012-07-03 Medtronic, Inc. System and method for utilizing brain state information to modulate cardiac therapy
US8041418B2 (en) * 2004-12-17 2011-10-18 Medtronic, Inc. System and method for regulating cardiac triggered therapy to the brain
US8112153B2 (en) 2004-12-17 2012-02-07 Medtronic, Inc. System and method for monitoring or treating nervous system disorders
US8112148B2 (en) 2004-12-17 2012-02-07 Medtronic, Inc. System and method for monitoring cardiac signal activity in patients with nervous system disorders
US8485979B2 (en) 2004-12-17 2013-07-16 Medtronic, Inc. System and method for monitoring or treating nervous system disorders
US20070239230A1 (en) * 2004-12-17 2007-10-11 Medtronic, Inc. System and method for regulating cardiac triggered therapy to the brain
US8108046B2 (en) * 2004-12-17 2012-01-31 Medtronic, Inc. System and method for using cardiac events to trigger therapy for treating nervous system disorders
US8209019B2 (en) * 2004-12-17 2012-06-26 Medtronic, Inc. System and method for utilizing brain state information to modulate cardiac therapy
US8108038B2 (en) * 2004-12-17 2012-01-31 Medtronic, Inc. System and method for segmenting a cardiac signal based on brain activity
US8209009B2 (en) 2004-12-17 2012-06-26 Medtronic, Inc. System and method for segmenting a cardiac signal based on brain stimulation
CN101124012B (en) 2004-12-27 2012-09-05 范因斯坦医学研究院 Device for treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US7991461B2 (en) * 2005-01-06 2011-08-02 Braingate Co., Llc Patient training routine for biological interface system
US8095209B2 (en) * 2005-01-06 2012-01-10 Braingate Co., Llc Biological interface system with gated control signal
WO2006074029A2 (en) * 2005-01-06 2006-07-13 Cyberkinetics Neurotechnology Systems, Inc. Neurally controlled and multi-device patient ambulation systems and related methods
US8812096B2 (en) * 2005-01-10 2014-08-19 Braingate Co., Llc Biological interface system with patient training apparatus
US20060167564A1 (en) * 2005-01-10 2006-07-27 Flaherty J C Limb and digit movement system
US7881780B2 (en) * 2005-01-18 2011-02-01 Braingate Co., Llc Biological interface system with thresholded configuration
US8600521B2 (en) * 2005-01-27 2013-12-03 Cyberonics, Inc. Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity
US7561918B2 (en) 2005-01-28 2009-07-14 Cyberonics, Inc. Autocapture in a neurostimulator
US7454245B2 (en) 2005-01-28 2008-11-18 Cyberonics, Inc. Trained and adaptive response in a neurostimulator
US7493161B2 (en) 2005-05-10 2009-02-17 Cardiac Pacemakers, Inc. System and method to deliver therapy in presence of another therapy
US20070027499A1 (en) * 2005-07-29 2007-02-01 Cyberonics, Inc. Neurostimulation device for treating mood disorders
US7499752B2 (en) * 2005-07-29 2009-03-03 Cyberonics, Inc. Selective nerve stimulation for the treatment of eating disorders
US20070025608A1 (en) * 2005-07-29 2007-02-01 Cyberonics, Inc. Enhancing intrinsic neural activity using a medical device to treat a patient
US8165682B2 (en) * 2005-09-29 2012-04-24 Uchicago Argonne, Llc Surface acoustic wave probe implant for predicting epileptic seizures
US8929991B2 (en) 2005-10-19 2015-01-06 Advanced Neuromodulation Systems, Inc. Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits
US20070088403A1 (en) * 2005-10-19 2007-04-19 Allen Wyler Methods and systems for establishing parameters for neural stimulation
US7856264B2 (en) * 2005-10-19 2010-12-21 Advanced Neuromodulation Systems, Inc. Systems and methods for patient interactive neural stimulation and/or chemical substance delivery
US20070088404A1 (en) * 2005-10-19 2007-04-19 Allen Wyler Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders
US7729773B2 (en) 2005-10-19 2010-06-01 Advanced Neuromodualation Systems, Inc. Neural stimulation and optical monitoring systems and methods
US7620455B2 (en) 2005-10-25 2009-11-17 Cyberonics, Inc. Cranial nerve stimulation to treat eating disorders
US7555344B2 (en) 2005-10-28 2009-06-30 Cyberonics, Inc. Selective neurostimulation for treating epilepsy
US7957796B2 (en) 2005-10-28 2011-06-07 Cyberonics, Inc. Using physiological sensor data with an implantable medical device
US20070106143A1 (en) * 2005-11-08 2007-05-10 Flaherty J C Electrode arrays and related methods
US7570999B2 (en) 2005-12-20 2009-08-04 Cardiac Pacemakers, Inc. Implantable device for treating epilepsy and cardiac rhythm disorders
US20100023021A1 (en) * 2005-12-27 2010-01-28 Flaherty J Christopher Biological Interface and Insertion
US20070156126A1 (en) * 2005-12-29 2007-07-05 Flaherty J C Medical device insertion system and related methods
US20070149952A1 (en) * 2005-12-28 2007-06-28 Mike Bland Systems and methods for characterizing a patient's propensity for a neurological event and for communicating with a pharmacological agent dispenser
US7657310B2 (en) 2006-01-26 2010-02-02 Cyberonics, Inc. Treatment of reproductive endocrine disorders by vagus nerve stimulation
US7974697B2 (en) * 2006-01-26 2011-07-05 Cyberonics, Inc. Medical imaging feedback for an implantable medical device
US7801601B2 (en) * 2006-01-27 2010-09-21 Cyberonics, Inc. Controlling neuromodulation using stimulus modalities
US20070287931A1 (en) * 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US7787945B2 (en) * 2006-03-08 2010-08-31 Neuropace, Inc. Implantable seizure monitor
US20080058785A1 (en) 2006-04-12 2008-03-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Autofluorescent imaging and target ablation
US20120035437A1 (en) 2006-04-12 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Navigation of a lumen traveling device toward a target
US8326431B2 (en) * 2006-04-28 2012-12-04 Medtronic, Inc. Implantable medical device for the concurrent treatment of a plurality of neurological disorders and method therefore
US8086316B2 (en) * 2006-05-24 2011-12-27 Drexel University Wireless controlled neuromodulation system
US7391257B1 (en) * 2007-01-31 2008-06-24 Medtronic, Inc. Chopper-stabilized instrumentation amplifier for impedance measurement
US9615744B2 (en) * 2007-01-31 2017-04-11 Medtronic, Inc. Chopper-stabilized instrumentation amplifier for impedance measurement
WO2008103842A2 (en) * 2007-02-21 2008-08-28 Neurovista Corporation Methods and systems for characterizing and generating a patient-specific seizure advisory system
US20080249591A1 (en) * 2007-04-06 2008-10-09 Northstar Neuroscience, Inc. Controllers for implantable medical devices, and associated methods
US9554721B1 (en) 2007-04-23 2017-01-31 Neurowave Systems Inc. Seizure detector, brain dysfunction monitor and method
US8000788B2 (en) 2007-04-27 2011-08-16 Medtronic, Inc. Implantable medical device for treating neurological conditions including ECG sensing
US8781595B2 (en) 2007-04-30 2014-07-15 Medtronic, Inc. Chopper mixer telemetry circuit
US8224759B2 (en) * 2007-05-01 2012-07-17 Evolved Machines, Inc. Regulating activation threshold levels in a simulated neural circuit
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
EP2200692B1 (en) * 2007-09-26 2016-11-09 Medtronic, Inc. Frequency selective monitoring of physiological signals
US8571643B2 (en) 2010-09-16 2013-10-29 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8337404B2 (en) 2010-10-01 2012-12-25 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8382667B2 (en) 2010-10-01 2013-02-26 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
CN101925377A (en) * 2008-01-25 2010-12-22 麦德托尼克公司 The detection of Sleep stages
WO2009146030A1 (en) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US20090275997A1 (en) * 2008-05-01 2009-11-05 Michael Allen Faltys Vagus nerve stimulation electrodes and methods of use
EP2313148B1 (en) 2008-07-30 2013-08-21 Ecole Polytechnique Fédérale de Lausanne Apparatus for optimized stimulation of a neurological target
US8417344B2 (en) 2008-10-24 2013-04-09 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
CA2743575C (en) 2008-11-12 2017-01-31 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
AU2009316801C1 (en) * 2008-11-18 2015-12-24 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflammatory stimulation
WO2010075518A1 (en) * 2008-12-23 2010-07-01 Neurovista Corporation Brain state analysis based on select seizure onset characteristics and clinical manifestations
US8239028B2 (en) * 2009-04-24 2012-08-07 Cyberonics, Inc. Use of cardiac parameters in methods and systems for treating a chronic medical condition
US8172759B2 (en) * 2009-04-24 2012-05-08 Cyberonics, Inc. Methods and systems for detecting epileptic events using nonlinear analysis parameters
US8827912B2 (en) 2009-04-24 2014-09-09 Cyberonics, Inc. Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8886339B2 (en) * 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US20110137297A1 (en) * 2009-09-17 2011-06-09 Kiani Massi Joe E Pharmacological management system
US9770204B2 (en) 2009-11-11 2017-09-26 Medtronic, Inc. Deep brain stimulation for sleep and movement disorders
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CA2782710C (en) 2009-12-01 2019-01-22 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device and methods of making and using the same
EP3636314B1 (en) 2009-12-23 2021-09-08 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US20110218820A1 (en) * 2010-03-02 2011-09-08 Himes David M Displaying and Manipulating Brain Function Data Including Filtering of Annotations
US20110219325A1 (en) * 2010-03-02 2011-09-08 Himes David M Displaying and Manipulating Brain Function Data Including Enhanced Data Scrolling Functionality
EP2552536B1 (en) 2010-04-01 2016-06-08 Ecole Polytechnique Fédérale de Lausanne (EPFL) Device for interacting with neurological tissue
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8406868B2 (en) 2010-04-29 2013-03-26 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8562536B2 (en) 2010-04-29 2013-10-22 Flint Hills Scientific, Llc Algorithm for detecting a seizure from cardiac data
US8831732B2 (en) 2010-04-29 2014-09-09 Cyberonics, Inc. Method, apparatus and system for validating and quantifying cardiac beat data quality
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8649871B2 (en) 2010-04-29 2014-02-11 Cyberonics, Inc. Validity test adaptive constraint modification for cardiac data used for detection of state changes
US8679009B2 (en) 2010-06-15 2014-03-25 Flint Hills Scientific, Llc Systems approach to comorbidity assessment
US8641646B2 (en) 2010-07-30 2014-02-04 Cyberonics, Inc. Seizure detection using coordinate data
US9211411B2 (en) 2010-08-26 2015-12-15 Medtronic, Inc. Therapy for rapid eye movement behavior disorder (RBD)
EP2621333B1 (en) 2010-09-28 2015-07-29 Masimo Corporation Depth of consciousness monitor including oximeter
US8684921B2 (en) 2010-10-01 2014-04-01 Flint Hills Scientific Llc Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US8562523B2 (en) 2011-03-04 2013-10-22 Flint Hills Scientific, Llc Detecting, assessing and managing extreme epileptic events
US8562524B2 (en) 2011-03-04 2013-10-22 Flint Hills Scientific, Llc Detecting, assessing and managing a risk of death in epilepsy
US10226209B2 (en) 2010-10-15 2019-03-12 Brain Sentinel, Inc. Method and apparatus for classification of seizure type and severity using electromyography
PT2627244T (en) 2010-10-15 2018-10-30 Brain Sentinel Inc Apparatus with emg sensors for detecting seizures
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US9504390B2 (en) 2011-03-04 2016-11-29 Globalfoundries Inc. Detecting, assessing and managing a risk of death in epilepsy
US9498162B2 (en) 2011-04-25 2016-11-22 Cyberonics, Inc. Identifying seizures using heart data from two or more windows
US9402550B2 (en) 2011-04-29 2016-08-02 Cybertronics, Inc. Dynamic heart rate threshold for neurological event detection
EP2729063A4 (en) 2011-07-05 2015-03-18 Lgch Inc Method and apparatus for detecting seizures
US20140288667A1 (en) * 2011-10-04 2014-09-25 Thomas James Oxley Sensing or Stimulating Activity of Tissue
US9549677B2 (en) 2011-10-14 2017-01-24 Flint Hills Scientific, L.L.C. Seizure detection methods, apparatus, and systems using a wavelet transform maximum modulus algorithm
US8706240B2 (en) * 2011-12-09 2014-04-22 Boston Scientific Neuromodulation Corporation Method for direct modulation of the spinothalamic tract
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US10448839B2 (en) 2012-04-23 2019-10-22 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
US10220211B2 (en) 2013-01-22 2019-03-05 Livanova Usa, Inc. Methods and systems to diagnose depression
US9521979B2 (en) 2013-03-15 2016-12-20 Medtronic, Inc. Control of spectral agressors in a physiological signal monitoring device
US9056195B2 (en) 2013-03-15 2015-06-16 Cyberonics, Inc. Optimization of cranial nerve stimulation to treat seizure disorderse during sleep
US9439150B2 (en) 2013-03-15 2016-09-06 Medtronic, Inc. Control of spectral agressors in a physiological signal montoring device
US9585611B2 (en) 2014-04-25 2017-03-07 Cyberonics, Inc. Detecting seizures based on heartbeat data
US9302109B2 (en) 2014-04-25 2016-04-05 Cyberonics, Inc. Cranial nerve stimulation to treat depression during sleep
CN106455985B (en) 2014-05-16 2019-09-17 阿莱瓦神经治疗股份有限公司 With the device and production and preparation method thereof of nerve fiber interaction
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US9924904B2 (en) 2014-09-02 2018-03-27 Medtronic, Inc. Power-efficient chopper amplifier
WO2016057553A1 (en) 2014-10-07 2016-04-14 Masimo Corporation Modular physiological sensors
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
EP3282931A4 (en) 2015-04-17 2019-01-16 Brain Sentinel, Inc. Method of monitoring a patient for seizure activity
CN104970787A (en) * 2015-06-29 2015-10-14 苏州景昱医疗器械有限公司 Probe contact, probe module and multiparameter monitoring system
CN108513542B (en) 2015-10-20 2020-09-18 墨尔本大学 Medical device for sensing and/or stimulating tissue
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2017134587A1 (en) 2016-02-02 2017-08-10 Aleva Neurotherapeutics, Sa Treatment of autoimmune diseases with deep brain stimulation
BR112018071375A2 (en) 2016-04-19 2019-02-05 Brain Sentinel Inc systems and methods for the characterization of seizures
WO2018039117A1 (en) 2016-08-22 2018-03-01 Boston Scientific Neuromodulation Corporation Neuromodulation system for providing paresthesia and analgesia and a system with leads and with electrodes
EP3612268A4 (en) 2017-04-18 2021-02-24 The University Of Melbourne Endovascular device for sensing and or stimulating tissue
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
EP4153053A1 (en) 2020-05-21 2023-03-29 The Feinstein Institutes for Medical Research Systems and methods for vagus nerve stimulation
CN115530845A (en) * 2022-10-17 2022-12-30 常州瑞神安医疗器械有限公司 Method for detecting abnormal discharge in epilepsia electroencephalogram signal

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863625A (en) 1973-11-02 1975-02-04 Us Health Epileptic seizure warning system
US4566464A (en) * 1981-07-27 1986-01-28 Piccone Vincent A Implantable epilepsy monitor apparatus
US4867164A (en) 1983-09-14 1989-09-19 Jacob Zabara Neurocybernetic prosthesis
US5025807A (en) 1983-09-14 1991-06-25 Jacob Zabara Neurocybernetic prosthesis
WO1997026823A1 (en) * 1996-01-23 1997-07-31 University Of Kansas Systems for prediction, rapid detection, warning, prevention or control of changes in activity states in the brain
US5683422A (en) * 1996-04-25 1997-11-04 Medtronic, Inc. Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation
US5713923A (en) 1996-05-13 1998-02-03 Medtronic, Inc. Techniques for treating epilepsy by brain stimulation and drug infusion
EP0911061A2 (en) * 1997-10-27 1999-04-28 Neuropace, Inc. System for the treatment of neurological disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3967616A (en) * 1972-10-24 1976-07-06 Ross Sidney A Multichannel system for and a multifactorial method of controlling the nervous system of a living organism
US3850161A (en) * 1973-04-09 1974-11-26 S Liss Method and apparatus for monitoring and counteracting excess brain electrical energy to prevent epileptic seizures and the like
US3993046A (en) * 1974-11-06 1976-11-23 Heriberto Fernandez Seizure suppression device
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5304206A (en) * 1991-11-18 1994-04-19 Cyberonics, Inc. Activation techniques for implantable medical device
US5311876A (en) * 1992-11-18 1994-05-17 The Johns Hopkins University Automatic detection of seizures using electroencephalographic signals
US5349962A (en) * 1993-11-30 1994-09-27 University Of Washington Method and apparatus for detecting epileptic seizures
US5752979A (en) * 1996-11-01 1998-05-19 Medtronic, Inc. Method of controlling epilepsy by brain stimulation
US5928272A (en) * 1998-05-02 1999-07-27 Cyberonics, Inc. Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863625A (en) 1973-11-02 1975-02-04 Us Health Epileptic seizure warning system
US4566464A (en) * 1981-07-27 1986-01-28 Piccone Vincent A Implantable epilepsy monitor apparatus
US4867164A (en) 1983-09-14 1989-09-19 Jacob Zabara Neurocybernetic prosthesis
US5025807A (en) 1983-09-14 1991-06-25 Jacob Zabara Neurocybernetic prosthesis
WO1997026823A1 (en) * 1996-01-23 1997-07-31 University Of Kansas Systems for prediction, rapid detection, warning, prevention or control of changes in activity states in the brain
US5683422A (en) * 1996-04-25 1997-11-04 Medtronic, Inc. Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation
US5713923A (en) 1996-05-13 1998-02-03 Medtronic, Inc. Techniques for treating epilepsy by brain stimulation and drug infusion
EP0911061A2 (en) * 1997-10-27 1999-04-28 Neuropace, Inc. System for the treatment of neurological disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUCE J. FISCH: "Spehlmann's EEG Primer,Second Edition", 1991, ELSEVIER SCIENCES PUBLISHER BV
CRAIG G.VAN HORNE, SPENCER BEMENT, BARRY J.HOFFER AND GREG A.GERHARDT: ""Multichannel semiconductor-based electrodes for in vivo electrochemical and electro-physiological studies in rat CNS"", NEUROSCIENCE LETTERS, vol. 120, 1990, pages 249 - 252
H.QU AND J.GOTMAN: ""A Seizure Warning System for Long-term Epilepsy Monitoring"", NEUROLOGY, vol. 45, 1995, pages 2250 - 2254
I.OSARIO, M.FREI, D.LERNER, S.WILKINSON,: ""A Method for Accurate Automated Real-time Seizure Detection"", EPILEPSIA, vol. 36, no. 4, 1995

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930035B2 (en) 1998-08-05 2011-04-19 Neurovista Corporation Providing output indicative of subject's disease state
US9421373B2 (en) 1998-08-05 2016-08-23 Cyberonics, Inc. Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US9415222B2 (en) 1998-08-05 2016-08-16 Cyberonics, Inc. Monitoring an epilepsy disease state with a supervisory module
US7747325B2 (en) 1998-08-05 2010-06-29 Neurovista Corporation Systems and methods for monitoring a patient's neurological disease state
US7853329B2 (en) 1998-08-05 2010-12-14 Neurovista Corporation Monitoring efficacy of neural modulation therapy
US8762065B2 (en) 1998-08-05 2014-06-24 Cyberonics, Inc. Closed-loop feedback-driven neuromodulation
US9375573B2 (en) 1998-08-05 2016-06-28 Cyberonics, Inc. Systems and methods for monitoring a patient's neurological disease state
US9320900B2 (en) 1998-08-05 2016-04-26 Cyberonics, Inc. Methods and systems for determining subject-specific parameters for a neuromodulation therapy
US9113801B2 (en) 1998-08-05 2015-08-25 Cyberonics, Inc. Methods and systems for continuous EEG monitoring
US9042988B2 (en) 1998-08-05 2015-05-26 Cyberonics, Inc. Closed-loop vagus nerve stimulation
US8781597B2 (en) 1998-08-05 2014-07-15 Cyberonics, Inc. Systems for monitoring a patient's neurological disease state
US7367956B2 (en) 2003-10-02 2008-05-06 Medtronic, Inc. Patient sensory response evaluation for neuromodulation efficacy rating
US7206632B2 (en) 2003-10-02 2007-04-17 Medtronic, Inc. Patient sensory response evaluation for neuromodulation efficacy rating
US8868172B2 (en) 2005-12-28 2014-10-21 Cyberonics, Inc. Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
US9592004B2 (en) 2005-12-28 2017-03-14 Cyberonics, Inc. Methods and systems for managing epilepsy and other neurological disorders
US8725243B2 (en) 2005-12-28 2014-05-13 Cyberonics, Inc. Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US9044188B2 (en) 2005-12-28 2015-06-02 Cyberonics, Inc. Methods and systems for managing epilepsy and other neurological disorders
US7676263B2 (en) 2006-06-23 2010-03-09 Neurovista Corporation Minimally invasive system for selecting patient-specific therapy parameters
US9480845B2 (en) 2006-06-23 2016-11-01 Cyberonics, Inc. Nerve stimulation device with a wearable loop antenna
US8855775B2 (en) 2006-11-14 2014-10-07 Cyberonics, Inc. Systems and methods of reducing artifact in neurological stimulation systems
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
US9898656B2 (en) 2007-01-25 2018-02-20 Cyberonics, Inc. Systems and methods for identifying a contra-ictal condition in a subject
US9622675B2 (en) 2007-01-25 2017-04-18 Cyberonics, Inc. Communication error alerting in an epilepsy monitoring system
US8543199B2 (en) 2007-03-21 2013-09-24 Cyberonics, Inc. Implantable systems and methods for identifying a contra-ictal condition in a subject
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US9445730B2 (en) 2007-03-21 2016-09-20 Cyberonics, Inc. Implantable systems and methods for identifying a contra-ictal condition in a subject
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
WO2009055866A1 (en) * 2007-10-31 2009-05-07 Cochlear Limited Implantable medical prothesis system capable of detecting symptoms of medical conditions
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US11406317B2 (en) 2007-12-28 2022-08-09 Livanova Usa, Inc. Method for detecting neurological and clinical manifestations of a seizure
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US9289595B2 (en) 2009-01-09 2016-03-22 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
WO2011072684A1 (en) 2009-12-16 2011-06-23 Ictalcare A/S A system for the prediction of epileptic seizures
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts

Also Published As

Publication number Publication date
US6337997B1 (en) 2002-01-08
AU3554299A (en) 1999-11-23
AU744851B2 (en) 2002-03-07
US6018682A (en) 2000-01-25
CA2329782A1 (en) 1999-11-11
EP1075306A1 (en) 2001-02-14

Similar Documents

Publication Publication Date Title
US6018682A (en) Implantable seizure warning system
US6374140B1 (en) Method and apparatus for treating seizure disorders by stimulating the olfactory senses
US6529774B1 (en) Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation
DE60121614T2 (en) PROOF OF NEUROLOGICAL FUNCTIONAL DISORDERS
EP1385426B1 (en) Detection of neurological disorders using evoked response potentials
US6597954B1 (en) System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes
US8190248B2 (en) Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto
US7974696B1 (en) Closed-loop autonomic neuromodulation for optimal control of neurological and metabolic disease
US7231254B2 (en) Closed-loop feedback-driven neuromodulation
US9042988B2 (en) Closed-loop vagus nerve stimulation
US9113801B2 (en) Methods and systems for continuous EEG monitoring
US20030100931A1 (en) Brain signal feedback for pain management
EP1145736A2 (en) Multimodal neurostimulator
EP0904119A1 (en) Techniques for treating epilepsy by brain stimulation and drug infusion
EP1809369A2 (en) Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto
US20080021514A1 (en) Treatment and warning of recurring therapy and other events using an implantable device
US20220287646A1 (en) Denoising sensed signals from artifacts from cardiac signals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2329782

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 35542/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999917411

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999917411

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 35542/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999917411

Country of ref document: EP